Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Amortizatization of Intangibles (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Amortizatization of Intangibles for 3 consecutive years, with $291000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 72.07% to $291000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 19.73% decrease, with the full-year FY2025 number at $1.9 million, down 19.73% from a year prior.
  • Amortizatization of Intangibles was $291000.0 for Q4 2025 at Artiva Biotherapeutics, down from $357000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $1.0 million in Q4 2024 to a low of $159000.0 in Q3 2023.
  • A 3-year average of $466400.0 and a median of $362500.0 in 2024 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: skyrocketed 314.47% in 2024, then crashed 72.07% in 2025.
  • Artiva Biotherapeutics' Amortizatization of Intangibles stood at $283000.0 in 2023, then soared by 268.2% to $1.0 million in 2024, then plummeted by 72.07% to $291000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Amortizatization of Intangibles are $291000.0 (Q4 2025), $357000.0 (Q3 2025), and $509000.0 (Q2 2025).